Search results for "Infectious"

showing 10 items of 2953 documents

COVID-19: Relationship and Impact on Breastfeeding-A Systematic Review.

2021

COVID-19 is an infectious disease caused by the SARS-CoV-2 virus that was declared a Public Health Emergency of International Concern by the World Health Organization (WHO). One major problem faced is whether breastfeeding by mothers infected with the virus is safe. The objective of this work is to study the impact that the SARS-CoV-2 virus can have on breastfeeding, and whether the virus or antibodies can be transmitted from mother to child through milk. We carried out a systematic review of studies focusing on the impact of SARS-CoV-2 on breastfeeding by mothers infected with the virus. The bibliographic search was done through Medline (Pubmed), MedlinePlus and Google Scholar. From 292 re…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)breastfeedingvirusesBreastfeedingMEDLINEbreastmilkReviewMedlinePlusPregnancyvaccineMedicineHumansTX341-641Pregnancy Complications Infectiousinternet.websiteinternetPregnancyNutrition and DieteticsMilk HumanNutrition. Foods and food supplybusiness.industrySARS-CoV-2Public healthfungiCOVID-19Infantmedicine.diseaseInfectious Disease Transmission Verticalimmune systemBreast FeedingInfectious disease (medical specialty)Family medicineFemalebusinessBreast feedingFood ScienceNutrients
researchProduct

PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC

2021

The current COVID-19 pandemic requires revisiting our current approach to major blood disorders, including ITP (Immune Thrombocytopenia), stirring  up the production of several disease-specific practical guidelines. This report describes an updated version of consensus-based practical guidelines on the management of ITP, adapted to the Italian health system and social context.  It highlights the role of the hematologist in offering guidance for choosing differentiated approaches in relation to specific circumstances and is intended to provide them with a useful tool for sharing the decision-making process with their patients.
 Probably, the greatest risk to avoid for a patient with sus…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)business.industrymedicine.medical_treatmentSplenectomySocial environmentHematology030204 cardiovascular system & hematologyImmune thrombocytopenia03 medical and health sciencesTherapeutic approach0302 clinical medicineInfectious DiseasesBlood Disorderhemic and lymphatic diseasesPandemicmedicine030212 general & internal medicineHematologistIntensive care medicinebusinessMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Chest trauma: First 48 hours management

2017

International audience; Chest trauma remains an issue for health services for both severe and apparently mild trauma management. Severe chest trauma is associated with high mortality and is considered liable for 25% of mortality in multiple traumas. Moreover, mild trauma is also associated with significant morbidity especially in patients with preexisting conditions. Thus, whatever the severity, a fast-acting strategy must be organized. At this time, there are no guidelines available from scientific societies. These expert recommendations aim to establish guidelines for chest trauma management in both prehospital an in hospital settings, for the first 48 hours. The ``Societe francaise d'ane…

medicine.medical_specialtyCritical CareThoracic InjuriesReferralDelphi methodGuidelines as TopicCritical Care and Intensive Care Medicine03 medical and health sciencesHealth services0302 clinical medicineBlunt[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesTrauma managementIntensive caremedicineHumansIn patient030212 general & internal medicineIntensive care medicinebusiness.industryHigh mortality030208 emergency & critical care medicineGeneral Medicine3. Good health[ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAnesthesiology and Pain MedicinePractice Guidelines as TopicEmergency medicinebusinessCase Management
researchProduct

Direct-acting antivirals ombitasvir/paritaprevir/rotonavir+dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatme…

2018

Background: The current international multicentre open-label, uncontrolled, real-world retrospective study aimed at evaluating the effectiveness and safety of ombitasvir / paritaprevir / ritonavir + dasabuvir ± ribavirin (3D therapy) in treatment-naive and treatment-experienced hepatitis C virus (HCV) genotype 1-infected (GT1) patients. Methods: Adult patients with chronic HCV GT1 infection, scheduled for 3D therapy according to therapeutic guidelines, were eligible. Demographic and clinical data were collected retrospectively by reviewing individuals health records. The primary effectiveness endpoint was the sustained virological response at 12 weeks following the end of treatment (SVR12).…

medicine.medical_specialtyDasabuvirCirrhosisHepatologymedicine.diagnostic_testbusiness.industryRibavirinmedicine.diseaseOmbitasvir03 medical and health scienceschemistry.chemical_compoundRegimen0302 clinical medicineInfectious DiseaseschemistryParitaprevirInternal medicinemedicine030211 gastroenterology & hepatologyRitonavir030212 general & internal medicineChronic hepatitis C ; genotype-1HCV ; ombitasvir ; paritaprevir ; dasabuvir ; cirrhosis ; liver transplant ; 3D therapyLiver function testsbusinessmedicine.drug
researchProduct

Review of European and American guidelines for the diagnosis of Lyme borreliosis

2019

International audience; Lyme disease is a tick-borne bacterial disease with polymorphic clinical manifestations (cutaneous, rheumatological, and neurological). In recent years the issue of the diagnosis of this infection has been highly publicized on the Internet and other media in Europe and America. Some patients and physicians may share the perception that the diagnosis of the infection is not reliable in France. We reviewed current European and American guidelines on Lyme disease and performed a methodological evaluation of all guidelines. We retrieved 16 guidelines from seven countries. Our analysis revealed a global consensus regarding diagnosis at each stage of the infection. All gui…

medicine.medical_specialtyDiagnostic methodsRecommandationsGuidelinesSerologyDiagnosis Differential03 medical and health sciencesLyme disease[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesBorreliamedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyComputingMilieux_MISCELLANEOUSLyme Disease[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseases0303 health sciencesBacterial diseasebiology030306 microbiologyLyme borreliosisbusiness.industryBorreliabiology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyUnited States3. Good healthLYMEEuropeInfectious DiseasesFamily medicinePractice Guidelines as Topic[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyLymeErythema migransbusinessMédecine et Maladies Infectieuses
researchProduct

Efavirenz induces alterations in lipid metabolism through AMPK activation

2008

Summary of results EFV produced an immediate reduction of mitochondrialfunction, evident by the significant and dose-dependentinhibition of mitochondrial O2 consumption and thedecrease of intracellular ATP and Δψm. This metabolicstress promoted the activation of AMPK, triggering severalof its signalling pathways, as EFV induced an increment inCD36 mRNA expression and in intracellular lipid content,which could have been a result of the formation of lipiddroplets. This intracellular lipid increase was not presentin cells treated with Compound C, which points to a keyrole for AMPK in these mechanisms. Conclusion Given that EFV treatment is usually prolonged, thesemechanisms may effect the gene…

medicine.medical_specialtyEfavirenzbusiness.industryPublic Health Environmental and Occupational HealthAMPKLipid metabolismmedicine.diseasechemistry.chemical_compoundInfectious DiseasesEndocrinologychemistryInternal medicinemedicineLipodystrophybusinessProtein kinase ALipoatrophyIntracellularCompound cJournal of the International AIDS Society
researchProduct

CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL

2019

Thromboembolic and bleeding events pose a severe risk for patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Many factors can contribute to promoting the thrombotic event due to the interaction between platelets, leukocytes, and endothelium alterations. Moreover, a significant role can be played by cardiovascular risk factors (CV.R) such as cigarette smoking habits, hypertension, diabetes, obesity and dyslipidemia. In this study, we evaluated the impact that CV.R plays on thrombotic risk and survival in patients with PV and ET .

medicine.medical_specialtyEndotheliumGastroenterologySettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicinePolycythemia veraInternal medicineDiabetes mellitushemic and lymphatic diseasesmedicinePlateletEssential ThrombocythemiaPolycythemia VeraThrombotic riskEssential thrombocythemiabusiness.industrylcsh:RC633-647.5Hematologylcsh:Diseases of the blood and blood-forming organsmedicine.diseaseObesityPolycythemia vera Essential ThrombocytemiaInfectious Diseasesmedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticlebusinessDyslipidemia030215 immunologyMediterranean Journal of Hematology and Infectious Diseases
researchProduct

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

2011

Abstract The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection fro…

medicine.medical_specialtyEndotheliummedicine.medical_treatmentlcsh:MedicineInflammationReviewAscorbic AcidMicrobiologyGastroenterologyGeneral Biochemistry Genetics and Molecular BiologySepsisNeoplasmsSepsisInternal medicinemedicineHumansEndotheliumAscorbic Acid DeficiencyCancerImmunology and Infectious DiseaseMedicine(all)Biochemistry Genetics and Molecular Biology(all)business.industrylcsh:RImmunityCancerGeneral Medicinemedicine.diseaseAscorbic acidSystemic inflammatory response syndromemedicine.anatomical_structureOncologyInjections IntravenousImmunologyAscorbic Acid DeficiencyIntravenous ascorbic acidmedicine.symptombusinessAdjuvantJournal of Translational Medicine
researchProduct

Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A

1998

Abstract Background The antipsoriatic drugs cyclosporin A (CyA) and etretinate have been found to influence proinflammatory eosinophilic leukocytes and pruritus. Aim We compared the number of blood eosinophils, concentration of serum eosinophil cationic protein (ECP), and pruritus in patients with psoriasis treated with either CyA or etretinate. Study design Patients with psoriasis vulgaris were randomly assigned to treatment for 10 weeks with either CyA ( n =21) or etretinate ( n =10). The psoriasis area-and-severity index (PASI-score) and pruritus (according to a 0–3 scale) served as clinical parameters, the blood esosinophil counts (Coulter Counter) and the serum ECP (RIA, Pharmacia) as …

medicine.medical_specialtyEosinophil cationic proteinbusiness.industryKeratolyticEtretinateDermatologymedicine.diseaseGastroenterologyBlood proteinsProinflammatory cytokineInfectious DiseasesPsoriasisInternal medicineCyclosporin aEosinophilicImmunologymedicinebusinessmedicine.drugJournal of the European Academy of Dermatology and Venereology
researchProduct

Adenosine triphosphate bioluminescence in intensive care units: Be careful with its use

2016

LETTER TO EDITOR

medicine.medical_specialtyEpidemiologyIntensive Care UnitMEDLINEInfection controlPilot Projects030501 epidemiologylaw.invention03 medical and health scienceschemistry.chemical_compoundAdenosine Triphosphate0302 clinical medicinelawIntensive careInfection controlMedicineBioluminescence030212 general & internal medicineIntensive care medicinebusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthIntensive care unitDisinfectionIntensive Care UnitsInfectious Diseaseschemistry0305 other medical sciencebusinessAdenosine triphosphateAmerican Journal of Infection Control
researchProduct